Biomarker of Pulmonary Exacerbation in Patients with CF
Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Multiple systemic antibiotics
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
A biomarker is a biochemical or a substance in the body that can be used to measure disease activity or effects of treatment. There is a need to identify biomarkers in CF that can be used to more quickly evaluate potential new treatments. Pulmonary exacerbations provide a nice opportunity to define the effect of intravenous antibiotics on candidate biomarkers and to determine whether clinical improvements are related to changes in bloodstream biomarkers.
>= 10 Years
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Additional key eligibility criteria: Initiation of IV antibioic therapy for a clinially diagnosed acute pulomonary exacerbation.
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
FOR MORE INFORMATION:
Sponsor Contact Information:
Sagel, Scott (720) 777-5546 email@example.com